NEW YORK (TheStreet) -- Drug company Bristol Myers Squibb reported third-quarter earnings of 61 cents a share, above the average analyst estimate of 58 cents. The company also revised its full-year guidance to $2.25 to $2.30 a share from $2.20 to $2.30 a share. The earnings release comes on the heels of Bristol-Myers Squibb's announcement that it will develop a once-a-day pill to treat HIV patients by combining its Reyataz treatment with an experimental drug from Gilead Sciences. ... Click to view a price quote on PG. Click to research the Consumer Non-Durables industry.